biotech
<a href="https://www.fiercebiotech.com/biotech/analysts-cut-engene-cancer-sales-forecast-after-updated-data-widen-gap-jj" hreflang="en">Analysts cut enGene cancer sales forecast after updated data widen gap to J&J</a>
FierceBiotech
May 11, 2026 · 21s listen
Listen · FierceBiotech
<a href="https://www.fiercebiotech.com/biotech/analysts-cut-engene-cancer-sales-forecast-after-updated-data-widen-gap-jj" hreflang="en">Analysts cut enGene cancer sales forecast after updated data widen gap to J&J</a>
0:00-0:21
Live · Kokoro-82M
Audio pre-rendered by Storyflo · cached + delivered from the edge
Leerink Partners analysts slashed their sales forecast for enGene Therapeuticsâ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals, including Johnson & Johnson.
Share
Send this story to anyone â or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to FierceBiotech.
Heard via Storyflo
Get audio versions of every article you read.
Pick what matters â your audio curator gets you into your daily flo.